An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV Compared With Engerix-B in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2014
At a glance
- Drugs V 270 (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics; Registrational
- Sponsors Dynavax Technologies
- 16 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-022372-31).
- 28 Mar 2012 Trial phase III identified as reported by European Clinical Trials Database record.